PROTECT MULTI AKTIENANLEIHE - ROCHE GS/BIONTECH ADR/NOVARTIS N Stock

Certificat

DE000VU9PMR6

Delayed Deutsche Boerse AG 13:42:31 2024-05-10 EDT
100.2 EUR +0.18% Intraday chart for PROTECT MULTI AKTIENANLEIHE - ROCHE GS/BIONTECH ADR/NOVARTIS N
Current month+0.82%
1 month+2.04%
Date Price Change Volume
24-05-10 100.2 +0.18% 0
24-05-09 100.1 +0.13% 0
24-05-08 99.94 -0.07% 0
24-05-07 100 0.00% 0
24-05-06 100 +0.02% 0

Delayed Quote Deutsche Boerse AG

Last update May 10, 2024 at 01:42 pm

More quotes

Static data

Product typeObligations Convertibles
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VU9PMR
ISINDE000VU9PMR6
Date issued 2023-07-07
Strike 268.6 CHF
Maturity 2024-07-19 (68 Days)
Parity 0.27 : 1
Emission price 100
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 101.5
Lowest since issue 89.98

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
225.1 CHF
Average target price
279.4 CHF
Spread / Average Target
+24.12%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW